A clinical trial to assess and compare overall survival (OS) between guadecitabine and treatment choice (TC) in adults with previously treated acute myeloid leukemia (AML) Un ensayo clínico para evaluar y comparar la supervivencia global entre la guadecitabina y la elección de tratamiento en adultos con leucemia mieloide aguda previamente tratada To assess and compare overall survival (OS) between guadecitabine and treatment choice (TC) in adults with previously treated acute myeloid leukemia (AML). TC options are: • High intensity (intermed...

• Country None
• organs None
• Specialty None

A study to test a new product AT13387 in lung cancer. Un estudio para probar un nuevo producto AT13387 en cáncer de pulmón Part A ?To establish the safety and maximum tolerated dose (MTD) of AT13387 when administered in combination with crizotinib. Part B ?To compare the PFS between the administration of single-agent cr...

• Country None
• organs None
• Specialty None

A clinical trial to investigate the safety and effect of a drug called AT13387 on its own or given with another drug Abiraterone Acetate on certain types of Prostate Cancer that does not respond to treatment with Abiraterone alone Part A: • To assess the safety and tolerability (incidence and severity of adverse events [AEs]) of the combination of AT13387 and abiraterone acetate and to select the most promising treatment regime...

• Country None
• organs None
• Specialty None

A study of SGI-110 in people with recurrent ovarian cancer who are also resistant to platinum treatment Stage 1 To assess the safety and tolerability of SGI-110+carboplatin and determine the maximum tolerated dose (MTD) for Stage 2 Stage 2 To assess and compare progression free survival (PFS) bet...

• Country None
• organs None
• Specialty None

Étude SGI-110-12 : étude d'extension de phase 2 chez les patients ayant précédemment participé à une étude évaluant la guadecitabine. Les syndromes myélodysplasiques sont des maladies de la moelle osseuse. Normalement, la moelle osseuse produit trois sortes de cellules sanguines : les globules rouges ou hématies, les globules blancs...

• Country France
• organs Leucémies aiguës, Syndromes myélodysplasiques (SMD)
• Specialty Chimiothérapie

Étude SGI-110-12 : étude d'extension de phase 2 chez les patients ayant précédemment participé à une étude évaluant la guadecitabine. [essai clos aux inclusions] Les syndromes myélodysplasiques sont des maladies de la moelle osseuse. Normalement, la moelle osseuse produit trois sortes de cellules sanguines : les globules rouges ou hématies, les globules blancs...

• Country France
• organs Leucémies aiguës, Syndromes myélodysplasiques (SMD)
• Specialty Chimiothérapie

A clinical trial to compare SGI-110 to other available treatments in patients with previously untreated Acute Myeloid Leukemia(AML) who are not considered suitable for intensive Chemotherapy To assess and compare efficacy (complete response [CR] rate) and overall survival (OS) between SGI-110 and TC (treatment choice) in adults with previously untreated AML who are not considered candidat...

• Country None
• organs None
• Specialty None

Étude ASTW660-01 : étude de phase 1-2 évaluant la sécurité, la pharmacocinétique et l’efficacité de l’ASTX660 chez des patients ayant une tumeur solide ou un lymphome métastatique ou non résécable. Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’à elles seules, elles représentent 90 % des cancers humains....

• Country France
• organs Tumeurs solides, Lymphomes non hodgkinien
• Specialty Thérapies Ciblées